

There is another way

Utilising ADCs to improve outcomes in patients with triple-negative and HR+/HER2-negative mBC

Saturday, 14 September 2024 | 13:00–14:30 CEST

Toledo Auditorium, Hall 3, Fira Barcelona Gran Via, Barcelona, Spain

AGENDA

13:00–13:05

Welcome and introduction



Dr Lisa Carey (US)

Deputy Director, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, US

13:05–13:20

ADCs as a treatment option in previously treated triple-negative and HR+/HER2-negative mBC



Dr Lisa Carey (US)

Deputy Director, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, US

13:20–14:00

Optimising treatment outcomes with ADCs in previously treated mTNBC and HR+/HER2-negative mBC



Dr Antonio Llombart Cussac (Spain)

Medical Oncologist, Chairman of the Medical Oncology Service, University Hospital Arnau de Vilanova, Valencia, Spain

14:00–14:20

Exploring ADCs as treatment options in earlier lines of mBC



Dr Sherene Loi (Australia)

Head of Translational Breast Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia

14:20–14:30

Q&A

All speakers – facilitated by the Chair Dr Lisa Carey (US)



Oncology

ADCs, antibody-drug conjugates; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; mTNBC, metastatic triple-negative breast cancer.

This symposium is sponsored and organised by Gilead and intended for healthcare professionals only.

The purpose of this symposium is scientific exchange. The audience is encouraged to actively participate in the discussion throughout the symposium after each presentation via the voting system and live during the Q&A.

GILEAD and the GILEAD logo are trade marks of Gilead Sciences, Inc. © 2024 Gilead Sciences, Inc. All rights reserved.

June 2024 IHQ-UNB-5923